CannTrust Holdings Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on CannTrust Holdings's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2019 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How CannTrust Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 19 | 55 | -12 | 50 | 0 |
31 Dec 18 | 46 | -14 | 43 | 0 |
30 Sep 18 | 36 | 18 | 32 | 0 |
30 Jun 18 | 30 | 18 | 25 | 0 |
31 Mar 18 | 26 | 19 | 20 | 0 |
31 Dec 17 | 21 | 7 | 14 | 0 |
30 Sep 17 | 16 | -7 | 10 | 0 |
30 Jun 17 | 10 | -11 | 7 | 0 |
31 Mar 17 | 7 | -13 | 6 | 0 |
31 Dec 16 | 4 | -13 | 5 | 0 |
31 Dec 15 | 1 | -6 | 4 | 0 |
Quality Earnings: CNTT.Q has a high level of non-cash earnings.
Growing Profit Margin: Insufficient data to determine if CNTT.Q's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CNTT.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare CNTT.Q's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if CNTT.Q's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: CNTT.Q has a negative Return on Equity (0%), as it is currently unprofitable.